Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy of MK-8931 in prodromal Alzheimer's disease
2015-002134-49Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) and Amnestic mild cognitive impairment due to Alzheimer's disease (MCI-AD) comparing MK-8931 active treatment with Placebo (2 arms). Started Aug 2015; status: completed.
02
Drugs
verubecestat
03
Conditions
Alzheimer's disease (AD)Amnestic mild cognitive impairment due to Alzheimer's disease (MCI-AD)
Beyond the preview
Go deeper on 2015-002134-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002134-49.